Cradle

Cradle published a technical explainer of its plate-level design philosophy, describing probabilistic modeling, “error fingerprints,” and portfolio-style optimization for consistent experimental rounds.

Cradle introduced “Guided Rounds,” describing best-practice workflow guidance inside the platform for setting up and running protein engineering rounds with defaults, process consistency, and traceable decision-making.

Cradle described how it kicks off antibody diversification campaigns when scientists have limited or no campaign-specific assay training data, including claims about affinity improvements and success patterns.

Cradle announced a partnership with H. Lundbeck A/S to deploy Cradle’s AI-powered protein design platform for end-to-end AI-guided protein engineering workflows, with initial focus on two antibody programs targeting CNS diseases.

Cradle announced $73m in Series B led by IVP, with continued backing from Index Ventures and Kindred Capital, and outlined plans to expand wet lab capabilities and scale go-to-market/operations.

Cradle announced a $24m Series A led by Index Ventures (with participation from Kindred Capital) and stated it had onboarded multiple industry partners and R&D projects focused on protein modalities and properties.

Cradle announced exiting stealth and raising a seed round (€5.5m / $5.4m), co-led by Index Ventures and Kindred Capital, including named angel investors; the company also described its wet lab and generative ML approach to protein design.